Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 13/20 | 0.75 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.75 |
| ▸ | DAGLB | Q8NCG7 | 7/20 | 0.50 |
| ▸ | DDHD2 | O94830 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18935799 | 1.00 | DAGLA (0.75) | DAGLAABHD6DAGLBDDHD2PARP1 | |
| SCHEMBL18935802 | 1.00 | DAGLA (0.75) | DAGLAABHD6DAGLBDDHD2PARP1 | |
| SCHEMBL20576205 | 0.92 | DAGLA (0.63) | DAGLAABHD6DAGLBDDHD2 | |
| SCHEMBL20575956 | 0.90 | DAGLA (0.60) | DAGLAABHD6DAGLBDDHD2 | |
| SCHEMBL20575954 | 0.90 | DAGLA (0.60) | DAGLAABHD6DAGLBDDHD2 | |
| SCHEMBL20576014 | 0.90 | DAGLA (0.60) | DAGLAABHD6DAGLBDDHD2 | |
| SCHEMBL18935645 | 0.90 | DAGLA (0.61) | DAGLAABHD6DAGLBDDHD2 | |
| SCHEMBL18921254 | 0.88 | DAGLA (0.58) | DAGLAABHD6DAGLBDDHD2 | |
| SCHEMBL18921279 | 0.86 | ABHD6 (0.74) | DAGLAABHD6DAGLBDDHD2GPR119 | |
| SCHEMBL18936194 | 0.86 | DAGLA (1.00) | DAGLAABHD6DAGLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017096315-A1 | TRIAZOLE DAGL(α) INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-06-08 | — | — | WO | disclosed |